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Background: Though percutaneous coronary intervention with the XIENCE V ever-
olimus-eluting stent (EES, Abbott Vascular, Santa Clara, CA) for native coronary artery
disease has favorable results compared to ﬁrst generation drug-eluting stents, outcomes
with EES for the treatment of in-stent restenosis (ISR) are unknown. The objective of this
study is to evaluate the safety and efﬁcacy of XIENCE V for the treatment of ISR.
Methods: XIENCE V USA is a prospective observational multicenter registry eval-
uating clinical outcomes in patients who received treatment with EES. In this study,
we present the 1-year clinical outcomes in patients who received EES for the treatment
of ISR and non-ISR in this registry. The primary outcome was the composite of target
lesion failure (deﬁned as cardiac death, target vessel myocardial infarction, or target
lesion revascularization). Secondary outcomes were myocardial infarction, target
lesion revascularization, and stent thrombosis.
Results: In this registry 383 patients (6411 years old; 68.4% male) received
revascularization for single-vessel ISR and 4832 patients (6411 years old; 69.0%
male) received revascularization for non-ISR lesions. At 1 year, the rate of clinical
adverse events (Table) was higher in the ISR group compared the non-ISR group,
however, these differences ceased to exist when case-control matched patients in the
non-ISR group were studied.
Conclusions: The treatment of ISR with EES appears to be safe and efﬁcacious at
1-year follow-up. Compared to the non-ISR group, the rate of target lesion failure was
much higher indicating a higher risk proﬁle of these patients. However, these
differences ceased to exist with case controlled matching.Table. Clinical outcomes at 1 year.
ISR Group (N=383)
Non-ISR Group
(N=4,832)
Case-Matched Non-
ISR Group (N=317)
Target Lesion Failure
(ARC MI)
12.5% 7.0% 10.5%
Myocardial Infarction
(ARC)
7.2% 5.8% 7.1%
Target Lesion
Revascularization
10.3% 2.9% 6.8%
Stent thrombosis
(ARC Deﬁnite)
1.7% 0.2% 0.7%TCT-456
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Background: Pathological studies have revealed atherosclerotic neointima (AN) after
stent implantation. However, the risk factor of neoatherosclerosis and its impact on
future clinical events remain unclear.
Methods: From the Kobe university OCT database, 137 consecutive patients (253
stents) who underwent OCT examination at >1 year after bare metal or ﬁrst-gener-
ation drug-eluting stent implantation were enrolled. We assessed AN (neointima
containing a diffuse border, signal-poor region with invisible struts underneath) by
follow-up OCT and compared major adverse cardiovascular event (MACE: death,
recurrent myocardial infarction and target lesion revascularization (TLR)) rate
between +AN and –AN group.
Results: 38 patients had AN at follow-up OCT, who had higher LDL-cholesterol and
high sensitivity CRP (hs-CRP) level. In multivariate logistic analysis, LDL cholesterol
and hs-CRP were the independent predictors of the presence of AN (OR 1.025
(P¼0.011), OR 1.016 (P¼0.045), respectively). The rate of MACE were signiﬁcantly
higher in +AN than in -AN for an average follow-up of 58 months after stenting. AfterB140 JACC Vol 62/18/Suppl B j October 27–November 1, 20multivariate cox hazard analysis, the presence of AN remained an independent risk
factor of MACE (HR 2.345, 95% CI 1.010-5.440, P¼0.047).Conclusions: Increased LDL-cholesterol and hs-CRP level may be risk factors for AN
progression in patients treated with coronary stents. In this study, the presence of AN
assessed by OCT were independently associated with MACE at >1 year after stent
placement, suggesting a need for careful clinical follow-up of patients with AN.
TCT-457
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Background: The clinical presentation of bare metal in-stent restenosis (ISR) is re-
ported to be associated with high rates of morbidity, including myocardial infarction
(MI). This study aimed to compare the clinical presentation and outcomes between
patients treated with 1st- versus 2nd-generation drug-eluting stents (DES) and pre-
sented with ISR on admission.
Methods: The study identiﬁed ﬁrst episode 1st or 2nd-generation DES ISR patients
who underwent re-intervention. The clinical presentation at admission was classiﬁed
as non acute (asymptomatic or stable angina) or acute (unstable angina, Canadian
Cardiovascular Society (CCS) III or IV and MI). We compared the 1st- vs. 2nd-gen
DES ISR clinical presentation and the rates of major adverse cardiac events (MACE)
as a composite of death, Q-wave MI and target lesion revascularization at 6 months.
Results: Overall, 709 patients with 1095 DES ISR lesions (1st-gen DES n¼526; 2nd-
gen DES n¼113) were selected. The mean age was 65  10 years and diabetics
comprised 49%. Clinical presentation included asymptomatic/stable angina in 29%,
unstable angina in 62% and MI in 8%. Patients with 2nd-generation DES ISR were
less likely to present as MI(13% vs. 5%; p¼0.05) and with severe symptoms (73% vs.
49%, p<0.01) as compared to 1st-gen DES. The incidence of MACE in the 1st- and
2nd-gen DES at 6 months was 8% and 9%, respectively (p¼1.0).
Conclusions: 2nd-generation DES ISR clinical presentation appears to be more
benign with less frequency of MI and CCS III or IV symptoms compared to 1st-
generation DES. The rates of MACE were similar at 6 months.TCT-458
Angiographic localized haziness after drug-coated balloon angioplasty in de-novo
lesions does not increase the risk of acute coronary thrombosis
Theresa Weichert1, Annette Fengler1, Philip Steen1, Klaus Bonaventura1
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Background: Clinical studies demonstrated the effectiveness and safety of drug-coated
balloon (DCB) in various clinical scenarios and support the use of paclitaxel-coated
balloon for the treatment of in-stent restenosis, of small coronary arteries and bifurcation
lesions.A fewsmall scale studies have reported excellent immediate and short term results
of DCB use compared to non-coated balloon for de-novo lesions. Initial angiographic13 j TCT Abstracts/POSTER/In-stent Restenosis and Stent Thrombosis
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multiple intimal ﬂaps, dissection and atheromatous tissues. We analyzed the safety,
focused on the rates of acute thrombosis after DCB in de-novo lesions without additional
stenting (the so called drug-eluting balloon only strategy) in a clinical setting.
Methods: A retrospective review was done of 191 consecutive patients who under-
went percutaneous coronary intervention procedure with the paclitaxel eluting balloon
SeQuent Please at a high-volume Heart Center in Potsdam. DCB was used for the
treatment of de-novo lesions in 85 patients (male n¼61, age 67.1  10.9 years) in 102
interventions. Interventions included small coronary arteries, long lesions, ostial
lesions and bifurcation lesions. All patients were pretreated with aspirin and clopi-
dogrel/prasugrel (DAPT), which was continued for at least 4 weeks.
Results: A localized haziness at the treated segment was found in 17 interventions
(16.8%).Duringhospital staynoneof the 85patients (0%)hadsuffered fromacute coronary
thrombosis in the clinical setting. Unscheduled coronary angiography was performed in
one patient (1%) within 72 hours after DCB because of recurrent chest pain and showed an
excellent short-term result with TIMI III ﬂow and without need for revascularization.
Conclusions: Incidence of localized haziness after DCB angioplasty in de-novo
lesions is comparable to treatment with plain old balloon angioplasty and does not
increase the risk of acute coronary thrombosis.
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Background: Clinical studies demonstrated the safety and effectiveness of drug-
coated balloon (DCB) in various clinical scenarios and support the use of paclitaxel-
eluting balloon for the treatment of in-stent restenosis, of small coronary arteries and
bifurcation lesions. We analyzed and compared the safety, focused on the rates of late
coronary thrombosis (LT), after DCB in de-novo lesions without additional stenting -
the so called "Drug-eluting balloon only" strategy - in four current studies with the
outcome in a clinical setting.
Methods: A retrospective review was done of 191 consecutive patients who under-
went percutaneous coronary intervention procedure with the paclitaxel eluting balloon
SeQuent Please at a high-volume Heart Center in Potsdam. DCB was used for the
treatment of de-novo lesions in 85 patients (male n¼61, age 67.1  10.9 years) in 102
interventions. The primary evaluation was LT. Mean clinical follow-up was 16.3 
5.5 months. Duration of dual antiplatelet therapy was 5.4  4.1 months.
Results: DCB without additional stenting was used in different clinical and interven-
tional settings. During follow-up none of the 85 patients (0%) had suffered from late
coronary thrombosis in the clinical setting. This is remarkable since DCB were mostly
used in complex interventions. Three patients died due to renal failure, one of them after
elective cardiac surgery and one patient died due to non-cardiovascular disease. Four
DCB trials used the "Drug-eluting balloon only" strategy in de-novo lesions: PEPCAD I
SVD, PEPCAD V (side branch), PICCOLETO and DEBUIT. Summarizing the rates of
LT after 6 to 12 months LT was reported in none of the 179 patients (0%).
Conclusions: The use of DCB in de-novo coronary artery disease is not associated
with a higher rate of LT. Beside the proven efﬁcacy the possible reduction in the
duration of DAPT to one month may represent additional advantages regarding safety,
patient compliance and costs for the Drug-eluting balloon only strategy. Further larger
scale studies are needed before DCB can be recommended for routine initial use in all
cases as an alternative approach.
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Background: In-stent restenosis (ISR) remains as a limitation of percutaneous
coronary intervention (PCI). Post-implantation stent expansion assessed by intravas-
cular ultrasound (IVUS) has been used to optimize PCI outcomes, but there are limited
data regarding on the effect of local stent expansion on ISR. The objective of this
study was to assess the relationship between local stent expansion and in-stent
hyperplasia (ISH) and lumen loss.
Methods: Vascular proﬁling (3-vessel 3D coronary reconstruction by angiography &
IVUS) was performed in 374 patients at baseline (BL) & 6-10 months follow-up (FU).
Each reconstructed coronary artery was divided into 1.5-mm segments for serial study.
A total of 80 bare-metal stents (BMS), 51 sirolimus-eluting stents (SES) and 25
paclitaxel-eluting stents (PES) were analyzed. At baseline, local stent expansion was
deﬁned as the ratio of stent area to the respective reference lumen area. Stent
expansion ratio was categorized as underexpansion (stent expansion <0.8), normal
(stent expansion 0.8-1.2) and overexpansion (stent expansion > 1.2).
Results: ISH area in overexpansion group is signiﬁcantly larger than in under-
expansion group at FU (3.3  2.0 mm2 vs 2.0  1.4 mm2, p<0.001 in BMS; 0.33 JACC Vol 62/18/Suppl B j October 27–November 1, 2013 j TCT Abstr0.53 mm2 vs 0.0036  0.028 mm2, p<0.001 in SES; and 0.71  0.78 mm2 vs 0.44 
0.42 mm2, p¼0.014 in PES). There was signiﬁcant lumen area decrease in over-
expansion group at FU compared to underexpansion group in all stent types (delta¼
3.3  2.0 mm2 vs 0.61  2.3 mm2, p<0.001 in BMS; delta¼ 0.55  1.5 mm2 vs -1.7
 1.6 mm2, p<0.001 in SES; and delta¼ 1.2  1.2 mm2 vs -0.52  1.1 mm2,
p<0.001 in PES). Lumen area in overexpansion group in SES became smaller than in
underexpansion group (8.1  1.5 mm2 vs 9.2  3.0 mm2, p¼0.01 in SES). In BMS
and PES, the relationship in lumen area at FU between overexpansion and under-
expansion groups were similar (8.7  2.5 mm2 vs 9.0  4.6 mm2, p¼0.58 in BMS;
8.1  1.2 mm2 vs 7.7  1.8 mm2, p¼0.12 in PES).
Conclusions: Overexpanded stent segment showed greater ISH and lumen loss at FU
regardless of stent type. There is less advantage of aggressive dilation at stent
deployment to get larger lumen.
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Background: The treatment of isolated in-stent restenosis (ISR) of the left-anterior-
descending artery (LAD) can be performed either with PCI with drug-eluting sten-
t(DES) or with surgical bypass with left-internal-mammary artery(LIMA). So far, no
data are available on the comparison between these two revascularization techniques
in this particular clinical context.
Methods: We compared clinical outcomes (MACCE:Major adverse cardiac cere-
brovascular events and procedure-related complications)of PCI with DES(DES group)
to surgery with LIMA(CABG group)for the treatment of pts with isolated LAD-
ISR.Continuous and categorical data were compared with t-Student and X2-test,res-
pectively.Kaplan-Meier method was used for comparisons during follow-up whereas
Cox-regression analysis to assess predictors of new revascularizations.
Results: We enrolled 141 consecutive patients with isolated LAD-ISR:70 pts in
PCI group and 71 pts in CABG group.The two groups were well-matched for
clinical characteristics. DES-ISR was present in 79% and BMS-ISR in 21% of
cases in the PCI group,while DES-ISR was found in 21% and BMS-ISR in 79% in
the CABG group(p<0.001).A 3-year clinical follow-up was achieved in>90%.
MACCE were observed in 22.8% of pts in PCI group and 30.9% in CABG group
(log-rank p ¼0.38).Target-lesion revascularization(TLR) was observed in 8.5% pts
in the PCI group whereas LIMA failure in 8.4% of the CABG group (P¼0.9).Non-
Target vessel revascularization occurred in 8.6 % and 14.1% of patients in the PCI
and CABG group,respectively (p¼0.22).At multivariable Cox-regression analysis,
predictors of any revascularization were chronic renal failure(HR 1.32; 95%CI
1.09-1.59),LDL-cholesterol levels(HR 1.29; 95%CI 1.09-1.51)and HbA1c levels
(HR 1.59; 95%CI 1.0-1.90). When compared with PCI group, CABG group was
characterized by higher rates of in-hospital complications/need for transfusion
(1.4% vs 28.1%, p<0.0001) and length of hospitalization (2.1 vs 5.7 days,
p<0.0001)
Conclusions: Isolated LAD-ISR may be effectively treated either PCI with DES and
CABG with LIMA. However, CABG treatment is characterized by higher rates of in-
hospital complications and requires longer hospitalization.
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Background: It was reported that peri-stent contrast staining (PSS) was one of
abnormal vessel reactions including incomplete stent apposition assessed with optical
coherence tomography. Little is known about the differences in temporal change of
PSS among various stents.
Methods: Between October 2001 and February 2012, percutaneous coronary inter-
vention was performed with bare-metal stent (BMS) in 2138 lesions and with drug-
eluting stent (DES) in 11138 lesions. We routinely performed follow-up coronary
angiography (CAG) at 6th and 18th month after BMS implantation and 8th and 20th
month after DES implantation, and found PSS in 56 lesions with BMS and 281 lesions
with DES (2.62% vs. 2.52%, p¼0.764). The temporal change of PSS between 6-8 and
18-20 months after stent implantation was conﬁrmed with CAG in 36 lesions with
BMS and 191 lesions with DES, which were classiﬁed into 3 groups: progressive,
unchanged, and regressive PSS. We examined the difference in temporal change of
PSS between DES and BMS. Furthermore, the temporal change after the 20th month
of stent implantation was examined with unscheduled CAG in 9 BMS lesions and 53
DES lesions. DES were classiﬁed into SES and non-SES.
Results: The results are shown in the ﬁgure. Progressive PSS after 20th month of stent
implantation was observed only in 9 of 43 lesions (20.9%) after SES implantation.acts/POSTER/In-stent Restenosis and Stent Thrombosis B141
